Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-1H and Stem Cell Transplantation for T-Cell Lymphoma
NCT00505921Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2003
- Primary completion
- Nov 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in peripheral T-cell lymphoma (PTCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression Free Survival at 2 years. Started Mar 2003; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT00505921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00505921.